Analyst consensus rating
BlossomHill Therapeutics Analyst Rating: Strong Buy
Direct answer
BlossomHill Therapeutics's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.20.
Forecast evidence checked September 7, 2026.
Get free BlossomHill Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $22.01
- Average price target
- $32.20
- High price target
- $36.00
- Low price target
- $28.00
- Low target gap
- +27.2%
- Target upside
- +46.3%
- High target gap
- +63.6%
- Target range width
- 36.3%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BlossomHill Therapeutics?
BlossomHill Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $32.20.
How far are BlossomHill Therapeutics's low and high targets from the recorded price?
The low target implies +27.2%, while the high target implies +63.6%.
How many analysts are included in BlossomHill Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is BlossomHill Therapeutics's target upside or downside calculated?
The average target of $32.20 is divided by the recorded price of $22.01, then one is subtracted to produce +46.3%. This does not guarantee a future return.
When was BlossomHill Therapeutics's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.